Italiano, Antoine
Cassier, Philippe A.
Lin, Chia-Chi
Alanko, Tuomo
Peltola, Katriina J.
Gazzah, Anas
Shiah, Her-Shyong
Calvo, Emiliano
Cervantes, Andrés
Roda, Desamparados
Tosi, Diego
Gao, Bo
Millward, Michael
Warburton, Lydia
Tanner, Minna
Englert, Stefan
Lambert, Stacie
Parikh, Apurvasena
Afar, Daniel E.
Vosganian, Gregory
Moreno, Victor
Funding for this research was provided by:
AbbVie
Article History
Received: 2 November 2020
Accepted: 18 May 2021
First Online: 3 July 2021
Declarations
:
: <b>Antoine Italiano:</b> Consulting/advisory role: Roche, Daiichi Sankyo, Immune Design, Epizyme, Bayer, Lilly; honoraria: Bayer, Daiichi Sankyo, Lilly, Epizyme, Novartis, Roche; research funding: Roche, Bayer, AstraZeneca/MedImmune, PharmaMar, MSD Oncology, Merck Serono. <b>Philippe A. Cassier:</b> Honoraria: Novartis, Roche/Genentech, Blueprint Medicines, Amgen; research funding: Novartis, Roche/Genentech, Lilly, Blueprint Medicines, Bayer, AstraZeneca, Celgene, Plexxikon, AbbVie, Bristol-Myers Squibb, Merck Serono, Merck Sharp & Dohme; Consultancy/advisory role: Merck Serono, Roche/Genentech. <b>Chia-Chi Lin:</b> Consulting/advisory role: Novartis, Boehringer Ingelheim, Blueprint Medicines; travel/accommodations/expenses: Lilly, Daiichi Sankyo, BeiGene, Novartis; honoraria: Novartis, Roche, Daiichi Sankyo. <b>Tuomo Alanko:</b> Consulting/advisory role: Bayer, Baxalta/Shire, BMS, Celgene, Eli Lilly, MSD, Nordic Drugs, Roche, Kaiku Health; research funding: AbbVie, Bayer, Boehringer Ingelheim, BMS, Debiopharm, Eli Lilly, Incyte, MSD, Pfizer, Roche; travel/accommodations/expenses: Baxalta/Shire, BMS, MSD, Pfizer, Roche. <b>Katriina J. Peltola:</b> Consulting/advisory role: Orion Pharma, BMS, MSD, Novartis, Pfizer, Ipsen, Roche, Varian; stockholder: Faron Pharmaceuticals; speakers’ bureau: BMS, Pfizer, MSD; expert testimony: Ipsen; travel/accommodations/expenses: Roche, BMS; research funding: AbbVie, Bayer, BMS, MSD, Roche, Exelixis, Orion Pharma, Eisai, Novartis. <b>Anas Gazzah:</b> Travel, accommodations, congress registration expenses: Boehringer Ingelheim, Novartis, Pfizer, Roche; consultant/expert role: Novartis; principal/sub-investigator of clinical trials: Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X BVBA, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Aveo, Bayer HealthCare Ag, BBB Technologies BV, BeiGene, BioAlliance Pharma, BioNTech AG, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co., Clovis Oncology, Daiichi Sankyo, Debiopharm SA, Eisai, Exelixis, Forma, GamaMabs, Genentech, Inc., Gilead Sciences, Inc, GlaxoSmithKline, Glenmark Pharmaceuticals, H3 Biomedicine, Inc, F. Hoffmann-La Roche AG, Incyte Corporation, Innate Pharma, Servier IRIS, Janssen, Kura Oncology, Kyowa Kirin Pharmaceutical Development, Lilly, Loxo Oncology, Lytix Biopharma AS, MedImmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology NV, OncoEthix, OncoMed, Oncopeptides, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Pfizer, PharmaMar, Pierre Fabre, Rigontec GmbH, Roche, Sanofi Aventis, Sierra Oncology, Taiho Pharma, Tesaro, Inc, Tioma Therapeutics, Inc., Xencor; research grants: AstraZeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi; nonfinancial support (drug supplied): AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Johnson & Johnson, Lilly, MedImmune, Merck, NH TherAGuix, Pfizer, Roche. <b>Her-Shyong Shiah:</b> The author declares no potential conflicts of interest. <b>Emiliano Calvo:</b> Consulting/advisory role: Novartis, Nanobiotix, Janssen-Cilag, PsiOxus, Seattle Genetics, EUSA Pharma, AbbVie, Celgene, AstraZeneca, Guidepoint Global, Roche/Genentech, GLG, Pfizer, Servier, amcure; speakers’ bureau: Novartis; research funding: AstraZeneca, BeiGene, Novartis, START; travel/accommodations/expenses reimbursement: Roche/Genentech; honoraria: HM Hospitales Group; stock/ownership interests: START, Oncoart Associated, International Cancer Consultants; president and founder of Foundation INTHEOS<b>. Andrés Cervantes:</b> Institutional research funding: AbbVie, Genentech, Merck Serono, BMS, MSD, Roche, BeiGene, Bayer, Servier, Lilly, Novartis, Takeda, Astellas, FibroGen; advisory board or speaker fees: Merck Serono, Roche, Bayer, Servier, Pierre Fabre. <b>Desamparados Roda:</b> The author declares no potential conflicts of interest. <b>Diego Tosi:</b> Consulting/advisory role: BioMarin (immediate family member); research funding: Novartis, Astellas, Janssen; patent pending on a new drug combination for prostate cancer treatment; travel/accommodations/expenses: Janssen, Pfizer, Astellas Pharma; immediate family member had travel/accommodations/expenses from Nutricia and Amicus. <b>Bo Gao:</b> Consulting/advisory role: MSD. <b>Michael Millward:</b> Consulting/advisory role: Merck Sharp & Dohme, Bristol-Myers Squibb, AstraZeneca, Roche, Pfizer, Takeda, Novartis; conference travel/support: Merck Sharp & Dohme, Bristol-Myers Squibb, AstraZeneca, Roche. <b>Lydia Warburton:</b> Travel/accommodations/expenses: MSD, Merck. <b>Minna Tanner:</b> Consulting/advisory role: Roche, Novartis, Pfizer; speakers’ bureau: Roche, Novartis, Pfizer, Amgen. <b>Gregory Vosganian:</b> Former employee of AbbVie and may own stock. <b>Stefan Englert, Stacie Lambert, Apurvasena Parikh, Daniel E. Afar:</b> AbbVie employees and may own stock. <b>Victor Moreno:</b> Consulting fees: Merck, BMS, Janssen, Pieris; travel/accommodations: Regeneron/Sanofi; presentations: Nanobiotix; educational grant: Medscape/Bayer.
: This study was approved by the institutional review board at each participating site prior to initiation of any screening or study-specific procedures. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, as defined by the International Conference on Harmonization. Written informed consent was obtained from each individual participating in the study.